Two suppliers, two datasheets, one claim: \u201cbioactive \u2014 forms apatite in simulated body fluid.\u201d One material later performs in animal studies. The other does nothing. Both datasheets were telling the truth.<\/p>\n
Simulated body fluid \u2014 a salt solution mimicking blood plasma\u2019s ion concentrations \u2014 became the biomaterials field\u2019s standard screen for bone-bonding potential: soak the material, look for an apatite layer. The method is official; as a 2020 review records, \u201cin 2007, the SBF was registered as ISO 23317, which is the standard solution for the in vitro evaluation of the apatite-forming ability of implant materials.\u201d<\/p>\n
How well does it work? The review\u2019s central statistic comes from an analysis of 33 published cases: \u201cin the clear majority of the studies (25\/33 cases), the SBF immersion test proved successful in predicting the relative in vivo bioactivity of the materials.\u201d Predictive, then \u2014 three times out of four. The other eight cases are where purchasing decisions go to die.<\/p>\n
Partly from chemistry the recipe leaves out. The review relays a standing critique: the test suffers from \u201cthe absence of proteins, whereas they are known to play an essential role in controlling apatite nucleation,\u201d from the Tris buffer added to hold pH, and from \u201cthe absence of any control for the carbonate content of the SBF solutions.\u201d And partly from procedure: \u201cfalse negative results (i.e., a material may be incorrectly considered non-bioactive) could be due to following non-standard experimental procedures.\u201d Even the ratio of powder to fluid changes outcomes \u2014 one cited recommendation fixes it at 1.5 mg\/mL for powders, a detail most certificates never mention.<\/p>\n
So a genuinely good material can flunk in a sloppy lab, and a mediocre one can pass in a generous protocol. The sceptics\u2019 position, quoted in the review, is that \u201cbioactivity cannot be predicted from observed apatite forming ability simply on immersion in a so-called simulated body fluid.\u201d The review\u2019s own stance is more moderate: a useful predictor \u2014 never proof.<\/p>\n
The parallel with other qualification tests is exact. A result that can be moved by recipe, ratio or refresh schedule is not a property of the material; it is a property of the experiment. That does not make it worthless \u2014 screening tests earn their keep by being cheap and early \u2014 but it moves the burden onto documentation. A 25-of-33 hit rate is respectable for a screen and inadequate for a promise, and the difference between those two uses is whether the protocol travels with the claim.<\/p>\n
Treat \u201cSBF-positive\u201d the way you would treat any test result travelling without its method: incomplete. The questions that make it meaningful are mechanical. Which SBF recipe, and per ISO 23317 or a variant? What mass-to-volume ratio? How many days, with the fluid refreshed how often? Characterised by which technique? A supplier who states protocol alongside result is showing you a measurement. One who states only the conclusion is showing you a word \u2014 and the eight-in-33 cases are a reminder of how much room that word leaves.<\/p>\n
Consistency is a property of methods before it is a property of materials. The suppliers worth keeping know their test as precisely as their powder.<\/p>\n